Innovent advances IBI363 into phase 3 MarsLight-11 trial in squamous NSCLC

• Innovent flagged new clinical data for IBI363, its PD-1/IL-2α-biased bispecific fusion protein, for presentation at ASCO 2026 in Chicago on May 29 to June 2.
• Presentations will cover proof-of-concept results in non-small cell lung cancer across immunotherapy-resistant patients and first-line treatment, positioning IBI363 as a potential new option in a high-need setting.
• Innovent has moved IBI363 into multiregional pivotal development for immunotherapy-resistant NSCLC, marking a step toward late-stage registration strategy.
• ASCO 2026 program also includes a phase 3 trial design disclosure for MarsLight-11, which will compare IBI363 with docetaxel in previously treated squamous NSCLC.
• Separate ASCO 2026 abstracts will present additional clinical studies involving TYVYT (sintilimab) across multiple tumor types, supporting lifecycle expansion efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604212000PR_NEWS_USPR_____CN39580) on April 22, 2026, and is solely responsible for the information contained therein.